Characteristics of pregnancy and delivery in patients with hyperparathyroidism

Primary hyperparathyroidism (PHPT) is a rare endocrine disease, but it is the most common cause of hypercalcemia in non-pregnant women. In the scientific literature and clinical practice of an obstetrician-gynecologist and endocrinologist, planning, pregnancy and the birth of a healthy child in a woman with PHPT are presented in rare cases and undoubtedly arouse scientific and practical interest. A clinical case from the practice of a gynecologist and endocrinologist of a patient who became pregnant against the background of hyperparathyroidism is presented. The history and clinical picture of the disease, the data of hormonal and instrumental methods of examination, and the treatment are described. A patient with hyperparathyroidism and pregnancy was observed by an endocrinologist and a gynecologist throughout the entire gestational period, the necessary laboratory and instrumental methods of examination, constant monitoring of the clinical condition, and correction of drug therapy were carried out in dynamics. Currently, there is no consensus on the treatment of PHPT during pregnancy, and an individualized approach to therapy is required for pregnant women with PHPT. The management of pregnancy in women with PHPT depends on the severity of symptoms, gestational age at the time of manifestation, age, concomitant diseases and complications. In women of childbearing potential with PHPT detected before pregnancy, it is essential to provide preconception counseling and radical surgery based on the underlying etiology of PHPT before conception. For optimal maternal and fetal outcomes, a multidisciplinary approach is recommended with close collaboration between an endocrinologist, obstetrician, and pediatrician. Special cases (parathyroid cancer, syndromic forms) should be accompanied by an individual treatment plan in a specialized endocrine department. The management of PHPT during pregnancy should be based on gestational age, severity of hypercalcemia, and the balance of risk and benefit to the mother and fetus.

1. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young J, Rejnmark L et al. Primary hyperparathyroidism: Review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28:1–19. https://doi.org/10.1007/s00198-016-3716-2.

2. Nadarasa K, Bailey M, Chahal H, Raja O, Bhat R, Gayle C et al. The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep. 2014;2014:140056. https://doi.org/10.1530/EDM-14-0056.

3. Marini F, Cianferotti L, Giusti F, Brandi ML. Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update. Clin Cases Miner Bone Metab. 2017;14(1):60–70. https://doi.org/10.11138/ccmbm/2017.14.1.060.

4. Davis C, Nippita T. Hyperparathyroidism in pregnancy. BMJ Case Rep. 2020;13(2):e232653. https://doi.org/10.1136/bcr-2019-232653.

5. Dale AG, Holbrook BD, Sobel L, Rappaport VJ. Hyperparathyroidism in Pregnancy Leading to Pancreatitis and Preeclampsia with Severe Features. Case Rep Obstet Gynecol. 2017;2017:6061313. https://doi.org/10.1155/2017/6061313.

6. Rigg J, Gilbertson E, Barrett HL, Britten FL, Lust K. Primary Hyperparathyroidism in Pregnancy: Maternofetal Outcomes at a Quaternary Referral Obstetric Hospital, 2000 Through 2015. J Clin Endocrinol Metab. 2019;104(3):721–729. https://doi.org/10.1210/jc.2018-01104.

7. Ali DS, Dandurand K, Khan AA. Primary Hyperparathyroidism in Pregnancy: Literature Review of the Diagnosis and Management. J Clin Med. 2021;10(13):2956. https://doi.org/10.3390/jcm10132956.

8. DiMarco AN, Meeran K, Christakis I, Sodhi V, Nelson-Piercy C, Tolley NS, Palazzo FF. Seventeen Cases of Primary Hyperparathyroidism in Pregnancy: A Call for Management Guidelines. J Endocr Soc. 2019;3(5):1009–1021. https://doi.org/10.1210/js.2018-00340.

9. Rey E, Jacob CE, Koolian M, Morin F. Hypercalcemia in pregnancy – a multifaceted challenge: case reports and literature review. Clin Case Rep. 2016;4(10):1001–1008. https://doi.org/10.1002/ccr3.646.

10. Mokrysheva NG, Eremkina AK, Mirnaya S, Rozhinskaya LY, Kuznetsov NS, Yesayan RM et al. A Case of Pregnancy Complicated by Primary Hyperparathyroidism Due to a Parathyroid Adenoma. Am J Case Rep. 2019;20:53–59. https://doi.org/10.12659/AJCR.912436.

11. Refardt J, Farina P, Hoesli I, Meier C. Hypercalcemic crisis in third trimenon: evaluating the optimal treatment strategy. Gynecol Endocrinol. 2018;34(10):833–836. https://doi.org/10.1080/09513590.2018.1462314.

12. Cassir G, Sermer C, Malinowski AK. Impact of Perinatal Primary Hyperparathyroidism on Maternal and Fetal and Neonatal Outcomes: Retrospective Case Series. J Obstet Gynaecol Can. 2020;42(6):750–756. https://doi.org/10.1016/j.jogc.2019.12.017.

13. Jones AR, Hare MJ, Brown J, Yang J, Meyer C, Milat F, Allan CA. Familial Hypocalciuric Hypercalcemia in Pregnancy: Diagnostic Pitfalls. JBMR Plus. 2020;4(6):e10362. https://doi.org/10.1002/jbm4.10362.

14. Tay D, Das JP, Yeh R. Preoperative Localization for Primary Hyperparathyroidism: A Clinical Review. Biomedicines. 2021;9(4):390. https://doi.org/10.3390/biomedicines9040390.

15. Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L et al. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2022;186(2):R33–R63. https://doi.org/10.1530/EJE-21-1044.

16. Appelman-Dijkstra NM, Ertl DA, Zillikens MC, Rjenmark L, Winter EM. Hypercalcemia during pregnancy: management and outcomes for mother and child. Endocrine. 2021;71(3):604–610. https://doi.org/10.1007/s12020-021-02615-2.

17. Sandler ML, Ho R, Xing MH, Gidumal S, Spitzer H, Levy JC, Chai RL. Primary Hyperparathyroidism During Pregnancy Treated With Parathyroidectomy: A Systematic Review. Laryngoscope. 2021;131(8):1915–1921. https://doi.org/10.1002/lary.29489.

18. Pereyra PLM, Aciar MLÁ, Fregenal MM, Ceballos GA, Ramírez Stieben LA. Primary hyperparathyroidism in pregnancy: a case report highlighting uncommon complication. Hiperparatiroidismo primario en el embarazo: reporte de caso destacando una complicación infrecuente. Medicina. 2024;84(2):342–346. Available at: https://pubmed.ncbi.nlm.nih.gov/38683521.

19. Bilezikian JP, Khan AA, Silverberg ShJ, Fuleihan GhEH, Marcocci C, Minisola S et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293–2314. https://doi.org/10.1002/jbmr.4677.

20. Bollerslev J, Schalin-Jantti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R et al. Management of endocrine disease: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019;181(3):P1–P19. https://doi.org/10.1530/EJE-19-0316.

21. Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1–G20. https://doi.org/10.1530/EJE-15-0628.

22. Zavatta G, Tebben PJ, McCollough CH, Yu L, Vrieze T, Clarke BL. Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2021;106(7):1900–1917. https://doi.org/10.1210/clinem/dgab162.

23. Khan AA, Koch CA, Van Uum S, Baillargeon JP, Bollerslev J, Brandi ML et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019;180(3):P1–P22. https://doi.org/10.1530/EJE-18-0609.

24. Kamenický P, Lecoq AL, Chanson P. Primary hyperparathyroidism in pregnancy. Ann Endocrinol. 2016;77(2):169–171. https://doi.org/10.1016/j.ando.2016.04.010.

25. Mantovani G, Bastepe M, Monk D, de Sanctis L, Thiele S, Usardi A et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol. 2018;14(8):476–500. https://doi.org/10.1038/s41574-018-0042-0.

26. Kovacs CS. Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery. Physiol Rev. 2016;96(2):449–547. https://doi.org/10.1152/physrev.00027.2015.

27. Hassan-Smith ZK, Criseno S, Gittoes NJL. Mild primary hyperparathyroidismto treat or not to treat? Br Med Bull. 2019;129(1):53–67. https://doi.org/10.1093/bmb/ldy042.

28. Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011;165(6):851–864. https://doi.org/10.1530/EJE-11-0589.

29. Dershem R, Gorvin CM, Metpally RPR, Krishnamurthy S, Smelser DT, Hannan FM et al. Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare Population. Am J Hum Genet. 2020;106(6):734–747. https://doi.org/10.1016/j.ajhg.2020.04.006.

30. Mouly C, Vargas-Poussou R, Lienhardt A, Silve C, Hureaux M, Magdelaine C et al. Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. Clin Endocrinol. 2020;93(3):248–260. https://doi.org/10.1111/cen.14211.